Defence Therapeutics DTCFF Stock
Defence Therapeutics Price Chart
Defence Therapeutics DTCFF Financial and Trading Overview
| Defence Therapeutics stock price | 0.42 USD |
| Previous Close | 0.45 USD |
| Open | 0.37 USD |
| Bid | 0.38 USD x 250000 |
| Ask | 0.45 USD x 500000 |
| Day's Range | 0.37 - 0.42 USD |
| 52 Week Range | 0.31 - 0.78 USD |
| Volume | 5K USD |
| Avg. Volume | 3.59K USD |
| Market Cap | 32.13M USD |
| Beta (5Y Monthly) | 1.394 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
DTCFF Valuation Measures
| Enterprise Value | 30.74M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -8.166 |
Trading Information
Defence Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.394 |
| 52-Week Change | -22.24% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.78 USD |
| 52 Week Low | 0.31 USD |
| 50-Day Moving Average | 0.39 USD |
| 200-Day Moving Average | 0.49 USD |
DTCFF Share Statistics
| Avg. Volume (3 month) | 3.59K USD |
| Avg. Daily Volume (10-Days) | 2.61K USD |
| Shares Outstanding | 75.79M |
| Float | 67.95M |
| Short Ratio | N/A |
| % Held by Insiders | 12.82% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.061% |
| Return on Equity (ttm) | -232.79% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -3764180 USD |
| Net Income Avi to Common (ttm) | -6046996 USD |
| Diluted EPS (ttm) | -0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.95M USD |
| Total Cash Per Share (mrq) | 0.04 USD |
| Total Debt (mrq) | 1.56M USD |
| Total Debt/Equity (mrq) | 28.89 USD |
| Current Ratio (mrq) | 3.367 |
| Book Value Per Share (mrq) | -0.01532664 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4533384 USD |
| Levered Free Cash Flow (ttm) | -2601942 USD |
Profile of Defence Therapeutics
| Country | United States |
| State | QC |
| City | Montreal |
| Address | 7171 Rue Frederick-Banting |
| ZIP | H4S1Z9 |
| Phone | 514 947 2272 |
| Website | https://defencetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.
Q&A For Defence Therapeutics Stock
What is a current DTCFF stock price?
Defence Therapeutics DTCFF stock price today per share is 0.42 USD.
How to purchase Defence Therapeutics stock?
You can buy DTCFF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Defence Therapeutics?
The stock symbol or ticker of Defence Therapeutics is DTCFF.
Which industry does the Defence Therapeutics company belong to?
The Defence Therapeutics industry is Biotechnology.
How many shares does Defence Therapeutics have in circulation?
The max supply of Defence Therapeutics shares is 75.78M.
What is Defence Therapeutics Price to Earnings Ratio (PE Ratio)?
Defence Therapeutics PE Ratio is now.
What was Defence Therapeutics earnings per share over the trailing 12 months (TTM)?
Defence Therapeutics EPS is -0.07 USD over the trailing 12 months.
Which sector does the Defence Therapeutics company belong to?
The Defence Therapeutics sector is Healthcare.